

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/04124 A1

- (51) International Patent Classification⁷: C07D 497/04, 495/04, A61K 31/4365, A61P 9/00, 11/00, 27/06, 37/08, A61M 11/00 // (C07D 497/04, 327:00, 221:00)
- (74) Agents: CIAMPORCERO, Audley, A. et al.; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).
- (21) International Application Number: PCT/US00/17310
- (22) International Filing Date: 23 June 2000 (23.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/143,354 12 July 1999 (12.07.1999) US
- (71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route 202, Raritan, NJ 08869-0602 (US).
- (72) Inventors: DODD, John, H.; 15 Alexandria Drive, Pittstown, NJ 08867 (US). HENRY, James, R.; 7307 Elm Ridge Drive, Indianapolis, IN 46236 (US). RUPERT, Kenneth, C.; 426 Centre Street, South Orange, NJ 07079 (US). BULLINGTON, James, L.; 21 Wesleyan Drive, Hamilton Square, NJ 08873 (US). HALL, Daniel, A.; 7 Continental Drive, Somerset, NJ 08873 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OXATHIEPINO[6,5-*b*]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS

(57) Abstract: This invention provides novel oxathiepino[6,5-*b*]dihydropyridines. These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Thus, this invention also provides pharmaceutical compositions, as well as methods, for preventing and treating disorders such as hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorders, gastrointestinal motility disorders and cardiovascular disorders.

WO 01/04124 A1

**OXATHIEPINO[6,5-*b*]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS
AND METHODS**

5

Field of the Invention

This invention relates to novel oxathiepino[6,5-*b*]dihydropyridines useful as calcium channel blockers. These compounds, and related pharmaceutical
10 compositions, are useful for treating and preventing a number of disorders such as hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorders, gastrointestinal motility disorders and cardiovascular disorders.

15 **Background of the Invention**

Thiacycloalkeno[3,2-*b*]pyridines are inhibitors of calcium ion uptake into smooth muscle tissue. They act to relax or prevent contraction of the tissue mediated by calcium mechanisms (Dodd et al., Drug Des. Discov. 1997 15:135-
20 48). These compounds are active antihypertensives and bronchodilators.

Thiacycloalkeno[3,2-*b*]pyridines are also useful for the treatment of cardiovascular disorders, including hypertension, ischemia, angina, congestive heart failure, migraine, myocardial infarction and stroke. Such compounds are
25 also useful for the treatment of other disorders such as hypersensitivity, allergy, asthma, dysmenorrhea, esophageal spasm, gastrointestinal motility disorders, glaucoma, premature labor and urinary tract disorders.

Dodd et al. evaluated a series of thiacycloalkeno[3,2-*b*]pyridines ranging in
30 sulfone ring size from five to nine membered for calcium antagonist activity. It was found that increasing the sulfone ring size from 5 to 8 members results in an *in vitro* potency increase of two orders of magnitude. Aromatic substitution patterns

which favor tracheal effects over aortic effects were found to be 2-NO₂ and 2-Cl, 6-F. The ester side chain which was found to maximize *in vivo* activity was the N-benzyl-N-methyl aminoethyl moiety (Dodd et al., Drug Des. Discov. 1997, 15:135-48, and Drug Des. Discov. 1993, 10:65-75).

5

Numerous compounds related to thiacycloalkenopyridines are known, as exemplified by the following publications. U.S. Pat. No. 5,708,177 to Straub discloses a process for the preparation of optically active ortho-substituted 4-aryl- or heteroaryl-1,4-dihydropyridines by oxidation and subsequent reduction from
10 their opposite enantiomers. U.S. Pat. No. 5,075,440 to Wustrow et al. discloses pyrido[2,3-f] [1,4]thiazepines and pyrido[3,2-b] [1,5]benzothiazepines which are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. U.S. Pat. Nos. 4,879,384 and 4,845,225, both to Schwender and Dodd, disclose substituted thiacycloalkeno [3,2-b] pyridines which
15 are also useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstrictor activity. U.S. Pat. Nos. 4,285,955 and 4,483,985 disclose acyclic sulfone substitution on simple dihydropyridines which possess calcium channel antagonist activity. U.S. Pat. No. 4,532,248 discloses a broad genus of dihydropyridines, including cyclic sulfones fused to a dihydropyridine
20 nucleus. Cardiogenic activity is disclosed for the entire genus. Finally, 10-Phenyl-2H-thiopyranol[3,2-b]quinolines are disclosed in Pagani, G.P.A., J. Chem. Soc. Perkin Trans. 2, 1392 (1974). However, none of these compounds is a calcium channel antagonist.

25

"Soft drugs" (also known as "antedrugs") are biologically active drugs which are metabolically inactivated after they achieve their therapeutic role at their designed site of action. The use of soft drugs, instead of their non-inactivatable analogs, avoids unwanted side effects. Soft drugs are known generally (see, for example, Biggadike et al., 2000, J. Med. Chem. 43:19-21; Lee et al., 1998, Curr.
30 Opin. Drug Disc. Dev. 1: 235-44). However, no dihydropyridine soft drugs are known.

Summary of the Invention

This invention provides novel compounds classified by Formula I as defined hereinbelow, as well as methods for making same. This invention also provides a
5 pharmaceutical composition comprising the instant compound and a pharmaceutically acceptable carrier.


This invention further provides a method of treating a subject suffering from a disorder whose alleviation is mediated by the reduction of calcium ion influx into
10 cells whose actions contribute to the disorder, which method comprises administering to the subject a therapeutically effective dose of the instant pharmaceutical composition.

This invention still further provides a method of inhibiting in a subject the
15 onset of a disorder whose alleviation is mediated by the reduction of calcium ion influx into cells whose actions contribute to the disorder, which method comprises administering to the subject a prophylactically effective dose of the instant pharmaceutical composition.

20 Finally, this invention provides an apparatus for administering to a subject the instant pharmaceutical composition, comprising a container and the pharmaceutical composition therein, whereby the container has a means for delivering to the subject a therapeutic and/or prophylactic dose of the pharmaceutical composition.

Detailed Description of the Invention

This invention provides a compound of Formula I,



Formula I

or a pharmaceutically acceptable salt thereof, wherein

(a) R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of H, OH, halogen, cyano, NO_2 , alkyl, C_{1-8} alkoxy, C_{1-8} alkylsulfonyl, C_{1-4} carboalkoxy, C_{1-8} alkylthio, difluoromethoxy, difluoromethylthio, trifluoromethyl and oxadiazole (formed by R_1 and R_2);

(b) R_6 is selected from the group consisting of H, C_{1-5} straight or branched alkyl, aryl, 3-piperidyl, N-substituted 3-piperidyl, N-substituted 2-pyrrolidinyl methylene and substituted alkyl, wherein

said N-substituted 3-piperidyl and said N-substituted 2-pyrrolidinyl methylene may be substituted with C_{1-8} straight or branched chain alkyl or benzyl, and said substituted alkyl may be substituted with C_{1-8} alkoxy, C_{2-8} alkanoyloxy, phenylacetyloxy, benzoyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, carboalkoxy or $\text{NR}'\text{R}''$, wherein

(i) R' and R'' are independently selected from the group consisting of H, C₁₋₈ straight or branched alkyl, C₃₋₇ cycloalkyl, phenyl, benzyl and phenethyl, or
(ii) R' and R'' together form a heterocyclic ring selected from the group consisting of piperidino, pyrrolidino, morpholino, thiomorpholino, piperazino, 2-thieno, 3-thieno and an N-substituted derivative of said heterocyclic rings, said N-substituted derivative being substituted with H, C₁₋₈ straight or branched alkyl, benzyl, benzhydryl, phenyl and/or substituted phenyl (substituted with NO₂, halogen, C₁₋₈ straight or branched chain alkyl, C₁₋₈ alkoxy and/or trifluoromethyl);

(c) R₇ is selected from the group consisting of H, amino, alkyl, aryl, trifluoromethyl, alkoxymethyl, 2-thieno and 3-thieno;


(d) R₉ is oxygen or sulfur; and

(e) n is an integer from 1 to 4.

In one embodiment of the instant compound, R₆ is -(CH₂)₂N(CH₃)CH₂PH or methyl. In another embodiment, R₇ is methyl. In a further embodiment, R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of H, halogen and NO₂. In the preferred embodiment, R₉ is oxygen.


The following compounds are exemplary of the present invention.

Compound 1: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(3-nitrophenyl), 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.




Compound 1

Compound 2: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, methyl ester, 1,1-dioxide.




Compound 2

Compound 3: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.



Compound 3


Compound 4: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(3-nitrophenyl), methyl ester, 1,1-dioxide.



Compound 4

5


Compound 5: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(2-nitrophenyl), methyl ester, 1,1-dioxide.



Compound 5


10

Compound 6: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(3-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, methyl ester, 1,1-dioxide.



Compound 6

Compound 7: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(3-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.




5

Compound 7

Compound 8: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(2-nitrophenyl), 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.


10



Compound 8

Compound 9: 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.


15



Compound 9

This invention also provides soft drug analogs of the compounds of
 5 Formula I. These soft drugs are characterized by a chemically labile moiety
 bound to the ester group in turn bound to the dihydropyridine ring structure. The
 soft drugs permit the instant drugs to exert their effect locally, and to subsequently
 be metabolized in the blood stream, thereby reducing unwanted systemic effects
 (e.g. low blood pressure). Use of such soft drug analogs permits the
 10 administration of greater doses of the claimed dihydropyridine compounds without
 subjecting the subject to intolerable levels of unwanted systemic effects.

Specifically, this invention provides a compound of Formula II,



15

or a pharmaceutically acceptable salt thereof, wherein

(a) R_1 , R_2 , R_3 , R_4 , and R_5 are independently selected from the group
 20 consisting of hydrogen, OH, halogen, cyano, NO_2 , alkyl, C_{1-8} alkoxy,

C₁₋₈ alkylsulfonyl, C₁₋₄ carboalkoxy, C₁₋₈ alkylthio, difluoromethoxy, difluoromethylthio, trifluoromethyl and oxadiazole (formed by R₁ and R₂);

- 5 (b) R₇ is selected from the group consisting of hydrogen, amino, alkyl, aryl, trifluoromethyl, alkoxymethyl, 2-thieno and 3-thieno;
- (c) R₈ is selected from the group consisting of -alkyl-OH, alkylamine, lactone, cyclic carbonate, alkyl-substituted cyclic carbonate, aryl-substituted cyclic carbonate, -aryl-C(O)OR', -alkyl-aryl-C(O)OR', -alkyl-OC(O)R', -alkyl-C(O)R', -alkyl-C(O)OR', -alkyl-N(R'')C(O)R', and -alkyl-N(R'')C(O)OR', wherein
- 10

R' and R'' are independently selected from the group consisting of hydrogen, amino, alkyl, aryl, aryl-fused cycloalkyl and heterocyclyl, the amino, alkyl, aryl, aryl-fused cycloalkyl and heterocyclyl being optionally substituted with halogen, cyano, NO₂, lactone, amino, alkylamino, aryl-substituted alkylamino, amide, carbamate, carbamoyl, cyclic carbonate, alkyl, halogen-substituted alkyl, arylalkyl, alkoxy, heterocyclyl and/or aryl (the aryl being optionally substituted with OH, halogen, cyano, NO₂, alkyl, amino, dimethylamino, alkoxy, alkylsulfonyl, C₁₋₄ carboalkoxy, alkylthio and/or trifluoromethyl); and

15

20

- 25 (d) R₉ is oxygen or sulfur.

Each of the preferred embodiments of the compounds of Formula I set forth above is also contemplated as an embodiment of the compounds of Formula II. In addition, in a preferred embodiment of the compound of Formula II, R₈ is selected from -alkyl-OH, lactone, cyclic carbonate, alkyl-substituted cyclic carbonate, aryl-

30

substituted cyclic carbonate, and -alkyl-OC(O)R' wherein R' is as described above.

The following compounds (referred to herein as compound nos.10-19) are also preferred embodiments of the present invention:

5 *5H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2,3-dichlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, 1,1-dioxide;

10 *5H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2,3-dichlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, (2-oxo-5-phenyl-1,3-dioxol-4-yl)methyl ester, 1,1-dioxide;

5H-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-hydroxyethyl ester, 1,1-dioxide;

15 *5H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(2-methyl-1-oxopropoxy)ethyl ester, 1,1-dioxide;

5H-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(2-methyl-1-oxopropoxy)ethyl ester, 1,1-dioxide;

20 *5H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-[(cyclopropylcarbonyl)oxy]ethyl ester, 1,1-dioxide;

5H-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(acetyloxy)ethyl ester, 1,1-dioxide;

25 *5H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-[(cyclohexylcarbonyl)oxy]ethyl ester, 1,1-dioxide;

5H-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(benzoyloxy)ethyl ester, 1,1-dioxide; and

30 *5H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 3-(benzoyloxy)propyl ester, 1,1-dioxide.

Unless specified otherwise, the term "alkyl" refers to a straight, branched or cyclic substituent consisting solely of carbon and H with no unsaturation. The term "alkoxy" refers to O-alkyl where alkyl is as defined supra. Illustrative aryl substituents include, for example, phenyl, naphthyl, diphenyl, fluorophenyl, difluorophenyl, benzyl, benzoyloxyphenyl, carboethoxyphenyl, acetylphenyl, ethoxyphenyl, phenoxyphenyl, hydroxyphenyl, carboxyphenyl, trifluoromethylphenyl, methoxyethylphenyl, acetamidophenyl, tolyl, xylol, dimethylcarbamyphenyl, $-(CH_2)_2N(CH_3)CH_2PH$, $-CH_2CH_2-N(Me)-CH_2$ -heteroaryl and the like. The term "halo" means fluoro, chloro, bromo and iodo. The symbol "Ph" refers to phenyl. "Independently" means that when there are more than one substituent, the substituents may be different.

The compounds of the instant invention are asymmetric in the dihydropyridine ring at the 4-position and thus exist as optical antipodes. As such, all possible optical isomers, antipodes, enantiomers or diastereomers resulting from additional asymmetric centers that may exist in optical antipodes, racemates and racemic mixtures thereof are also part of this invention. The antipodes can be separated by methods known to those skilled in the art such as, for example, fractional recrystallization of diastereomeric salts of enantiomerically pure acids. Alternatively, the antipodes can be separated by chromatography in a Pirkle type column.

As used herein, the phrase "pharmaceutically acceptable salt" means a salt of the free base which possesses the desired pharmacological activity of the free base and which is neither biologically nor otherwise undesirable. These salts may be derived from inorganic or organic acids. Examples of inorganic acids are hydrochloric acid, nitric acid, hydrobromic acid, sulfuric acid, and phosphoric acid. Examples of organic acids are acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,

methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, methyl sulfonic acid, salicylic acid and the like.

5 The instant compounds can be prepared using readily available starting materials. The first step of the synthesis as shown hereinafter in Scheme I is well known in the art (Shibata et al., Fuji Photo Film Co., Ltd., Jpn. Kokai Tokkyo Koho, p. 47; JP Patent 62253161, 1987; JP Patent Application 86-39760 (860224); Canadian Patent Application No. 429975, 1988).

10 This invention also provides a pharmaceutical composition comprising the instant compound and a pharmaceutically acceptable carrier.

Pharmaceutical compositions containing a compound of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, such as systemic administration, including but not limited to intravenous, oral, nasal or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical carriers may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, syrup and the like in the case of oral liquid preparations (for example, suspensions, elixirs and solutions), or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (for example, powders, capsules and tablets).

25 In a particular embodiment, the compounds of the instant invention are administered by inhalation. For inhalation therapy, the compound may be in a solution useful for administration by metered dose inhalers, or in a form suitable for a dry powder inhaler or insufflator. More particularly, the compounds for use in accordance with the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized container, a pack or a nebuliser, for

30

instance, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas inside such container. The dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges made of a pharmaceutically acceptable material such as gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

Because of their ease of administration, tablets and capsules represent an advantageous oral dosage unit form, wherein solid pharmaceutical carriers are employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients for solubility or preservative purposes may also be included. Injectable suspensions may also be prepared, wherein appropriate liquid carriers, suspending agents and the like may be employed. The compounds may also be administered in the form of an aerosol.

The instant pharmaceutical compositions will generally contain a per dosage unit (e.g., tablet, capsule, powder, injection, teaspoonful and the like) from about 0.001 to about 100 mg/kg, and preferably from about 0.01 to about 20 mg/kg of the instant compound. Methods are known in the art for determining therapeutically and prophylactically effective doses for the instant pharmaceutical composition. The effective dose for administering the pharmaceutical composition to a human, for example, can be determined mathematically from the results of animal studies.

The compounds of the present invention inhibit the uptake of calcium ions into smooth muscle, and therefore act to relax or prevent calcium ion-mediated contraction of smooth muscle tissue.

Thus, this invention further provides a method of treating a subject suffering from a disorder whose alleviation is mediated by the reduction of calcium ion influx into cells whose actions contribute to the disorder, which method comprises administering to the subject a therapeutically effective dose of the instant pharmaceutical composition. By way of example, in a subject suffering from asthma, the subject's airways are constricted due to contraction of airway smooth muscle cells ("SMC's"). Reducing the calcium influx into the SMC's, whose action contributes to the disorder, would be expected to alleviate the disorder.

This invention still further provides a method of inhibiting in a subject the onset of a disorder whose alleviation is mediated by the reduction of calcium ion influx into cells whose actions contribute to the disorder, which method comprises administering to the subject a prophylactically effective dose of the instant pharmaceutical composition.


In one embodiment, the disorder is selected from the group consisting of hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, a urinary tract disorder, a gastrointestinal motility disorder and a cardiovascular disorder. In the preferred embodiment, the disorder is asthma. The cardiovascular disorder can be, for example, hypertension, ischemia, angina, congestive heart failure, myocardial infarction or stroke.

As used herein, "treating" a disorder means eliminating or otherwise ameliorating the cause and/or effects thereof. "Inhibiting" the onset of a disorder means preventing, delaying or reducing the likelihood of such onset.

The term "subject" includes, without limitation, any animal or artificially modified animal. In the preferred embodiment, the subject is a human.

This invention further provides an apparatus for administering to a subject the instant pharmaceutical composition, comprising a container and the pharmaceutical composition therein, whereby the container has a means for delivering to the subject a therapeutic and/or prophylactic dose of the pharmaceutical composition. In the preferred embodiment, the apparatus is an aerosol spray device for treating and/or preventing asthma via topical respiratory administration.

Finally, as set forth in more detail below, this invention provides a process for preparing the compound of Formula I:



Formula I


This invention will be better understood by reference to the Experimental Details that follow, but those skilled in the art will readily appreciate that these are only illustrative of the invention as described more fully in the claims which follow thereafter. Additionally, throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.

Experimental Details

A. Schemes and Syntheses


Procedures for making dihydropyridines are well documented in the art as shown in Eistert et al. (Chem. Ber. 110, 1069-1085, 1977), G. A. Pagani (J. Chem. Soc., Perkin Trans. 2, 1392-7, 1974), Mason et al. (J. Chem. Soc. (C) 2171-76, 1967), E. A. Fehnel (J. Amer. Chem. Soc. 74, 1569-74, 1952), and M. Seiyaku (Japan Patent Application No. 58201764, 1984).

Scheme I shows the preparation of the compounds of Formula I:



Scheme I


The compounds of Formula II can be made in accordance with Scheme II (wherein compound 2a may be made in steps analogous to those in Scheme I and R₁₋₉ are as described above), preferably in the presence of K₂CO₃ or CsCO₃ in an organic solvent such as dimethylformamide (DMF).



Scheme II

The compounds of Formula II may also be made in accordance with

5 Scheme III (wherein compound 3a may be made in steps analogous to those in Scheme I, and R_{1-9} are as described above), preferably in the presence of formic acid or NaOH (aq), respectively.




Scheme III


The following examples describe in greater particularity the chemical
 5 synthesis of representative compounds of the present invention. The remaining
 compounds disclosed herein can be prepared similarly in accordance with one or
 more of these methods. No attempt has been made to optimize the yields
 obtained in these reactions, and it would be clear to one skilled in the art that
 variations in reaction times, temperatures, solvents and/or reagents could
 10 increase the yields.

Example 1


5 5H-[1,4]Oxathiepine[6,5-b]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide




The synthesis of Compound 3, which is shown in Scheme IV above, was performed as follows:




24.95g (269.7 mmoles) of epichlorohydrin was added dropwise by addition funnel to a solution of 21.07g (269.7 mmoles) of 2-mercaptoethanol in 100ml
 5 water and 21.33g (269.7 mmoles) of pyridine at 0°C. After addition was complete, the cooling bath was removed and solution stirred at room temperature for 6 hours. The reaction was then made acidic with 1N HCL solution and extracted 4x200ml EtOAc. The organic layers were separated, combined, dried over MgSO₄, filtered, and concentrated *in vacuo* to give 40.8g of a product of colorless
 10 oil (>100% yield). The synthesis of this product (2-[(oxiranylmethyl)thio]ethanol) is described in detail in the literature (*Benzyl alcohol-free rapid processing of silver halide color photographic print paper*, Shibata et al. (Fuji Photo Film Co., Ltd., Japan); Jpn. Kokai Tokkyo Koho, pp. 47; JP Patent 62253161, 1987; JP Patent Application JP 86-39760, 860224; Canadian Patent Application No. 429975,
 15 1988).



12.16g (304 mmoles) of sodium hydroxide was dissolved in 120ml of water. 40.8g (304 mmoles) of the crude epoxide was added dropwise by addition funnel.
 20 The reaction mixture was heated to reflux for 5 hours (during which time the reaction became very dark), cooled to room temperature, made acidic with 6N HCL solution and extracted with 4x400ml EtOAc. The organic layers were combined, dried over MgSO₄, filtered, and concentrated *in vacuo* to give 20.08g (150 mmoles) of a brown oil that moves slightly faster than starting material on
 25 TLC using 1:1 hexane/ethyl acetate to elute.




5 A 1 L 3-neck flask fitted with a thermometer, addition funnel, and air-driven stirrer was charged with 43.5g (214.1 mmol) of 85% 3-chloroperoxybenzoic acid and 260ml CHCl₃, and then cooled in an ice bath. 13.06g (97.32 mmol) of the crude sulfide in 200ml CHCl₃ was added dropwise by addition funnel over 1 hour. The cooling bath was then removed and the reaction slurry stirred at room temperature for 2 hours. The reaction was then filtered and the filtrate
10 concentrated *in vacuo*. The residue was treated with ether and decanted. The resultant oil was then treated with warm toluene and decanted to give 9.07g of a light brown oil. Column chromatography using 1% MeOH in EtOAc afforded 7.9g (47.53 mmol) of the sulfone as a light yellow oil.



15 To 7.9g (47.53 mmol) of alcohol in 125ml acetone at 0° was added 20ml (54 mmol, 1.1 equivalents) of freshly prepared 2.7M Jones reagent dropwise by addition funnel. The Jones reagent was prepared by carefully dissolving 5.34g of chromium trioxide in 4.6ml of concentrated sulfuric acid, and then carefully diluting
20 to 20ml total volume with water. The cooling bath was removed and the resultant slurry was stirred at room temperature overnight. The reaction slurry was then diluted with 200ml water and extracted with 4x200ml EtOAc. The organic layers were separated, combined, washed with 2x200ml water, dried over MgSO₄,
25 filtered and concentrated *in vacuo* to give a white residue. The residue was

trituated with ether/ethyl acetate and filtered to give 4.67g (28.44 mmoles) of the desired product as a white solid.




5

A solution of 25.43g (153.9 mmoles) of N-benzyl-N-methylethanol amine and 0.2ml triethylamine was warmed in an oil bath to 60°C. 13.6g (161.79 mmoles) of diketene was added dropwise by addition funnel, while keeping the reaction temperature between 60-85°C. After addition of diketene was complete, the reaction was stirred another 30 minutes, cooled to room temperature, and then cooled in an ice bath. 20ml of 2-Propanol was added. Ammonia gas was then bubbled through the reaction mixture for 2 hours. The orange reaction mixture was capped and allowed to stand overnight at 5°C. The reaction mixture was then stirred in an ice bath and 10ml of heptane was added. A precipitate began to form. After one hour the reaction slurry was filtered and the precipitate was washed with 3x40ml 10% v/v 2-propanol/heptane to give 21.15g (85.17 mmoles) of a white solid.


10

15



20

2.4g (14.62 mmoles) of the cyclic β -ketone sulfone ether, 2.06g (14.62 mmoles) of 2-chlorobenzaldehyde, and 3.63g (14.62 mmoles) of 2-(N-benzyl-N-methylamino)ethyl-3-aminocrotonate was heated to 110°C in 50ml DMF for 3.5 hours. The reaction was then cooled, diluted with 500ml EtOAc, washed with
5 4x200ml water, 1x100ml brine, dried over Na_2SO_4 , filtered and concentrated *in vacuo* to give a brown oil. Column chromatography using 3:2 EtOAc/hexane afforded 4.87g (9.42 mmoles) of the desired product (Compound 3) as a yellow foam.



10

4.87g (9.42 mmoles) of the dihydropyridine was taken up in 150ml ether containing a small amount of ethyl acetate. 1.08g (9.42 mmoles) of 85% orthophosphoric acid in 75ml ether was added dropwise by addition funnel over 90 minutes. The resultant white slurry was stirred for 4 hours and then filtered.
15 The resultant white solid was washed with excess ether and dried to give 2.68g (5.18 mmoles) of the phosphate salt.

B. Assays

Example 2

Assay for inhibition of nitrendipine binding

5

Female, New Zealand white rabbits (1-2 kg) are sacrificed by cervical dislocation, and the heart is immediately removed, cleaned and chopped into small pieces. The tissue is homogenized in 5x volume of 0.05M Hepes buffer, pH 7.4. The homogenate is centrifuged at 4000g for 10 minutes, and the supernatant is re-centrifuged at 42,000g for 90 minutes. The resulting membrane pellet is resuspended (0.7 ml/g weight) in 0.05M Hepes, pH 7.4 and stored at 70 °C until used. Each tube of the binding assay contains ³H-nitrendipine (0.05-0.50 nM), buffer, membranes (0.10 ml), and test compound in a total volume of 1.0 ml. After 90 minutes at 4 °C, the bound nitrendipine is separated from the unbound by filtration on Whatman GF/C filters. After rinsing, the filters are dried and counted in a liquid scintillation counter.

20

Non-specifically bound ³H-nitrendipine (i.e., the amount bound in the presence of excess unlabelled nitrendipine) is subtracted from the total bound to obtain specifically-bound radiolabeled nitrendipine. The amount of specifically-bound nitrendipine in the presence of a test compound is compared to the amount bound in the absence of the compound. A percent displacement (or inhibition) can then be obtained.

25

Example 3

Test for Inhibition of Calcium-Dependent Smooth Muscle Contraction

30

The trachea and the aorta from dogs sacrificed by excess KCl injection are stored overnight at 4 °C in oxygenated Krebs-Henseleit buffer. Tracheal rings, one cartilage segment wide (5-10 mm), are cut starting from the bronchial end. Rings of aorta tissue of the same width are also prepared. After cutting the

cartilage, the trachealis muscle tissue and the aorta tissue are suspended in oxygenated Krebs-Henseleit buffer at 37 °C in a 25 ml tissue bath. After a 60-minute equilibration period, the tissues are challenged with 10 µM carbachol. After 5 minutes, the tissues are rinsed and allowed to rest 50 minutes. The tissues are then challenged with 50 mM KCl and, after 30 minutes, the contractions are quantitated. The tissues are then rinsed and re-equilibrated for 50 minutes. Test compounds are then added for 10 minutes, and the tissue is rechallenged with 50 mM KCl. After 30 minutes, the contraction is recorded and used to determine the % inhibition of control. The percent inhibition of smooth muscle contraction is calculated as follows from response data before and after drug treatment:

$$\% \text{ inhibition} = 100 - 100 \times \frac{\text{peak response after drug treatment}}{\text{peak response before drug treatment}}$$


Table 1 below sets forth the mass spectra data, the inhibition of nitrendipine binding and inhibition of calcium-dependent smooth muscle contraction in terms of percent inhibition for selected compounds of Formula I.

Table 1

Compound Number	Molecular Wt	Amount Submitted	Nitrendipine Binding IC ₅₀ (nM)	% Yield	Trachea IC ₅₀ (nM)	Mass Spectroscopy
1	564.0589	.2355	39	27.8		M+H=528
2	383.8524	.1771	12	46.1		M+Na=406
3	552.51	.1051	129	19	55	M+H=517
4	394.4052	.1365	46	34.6		M+Na=417
5	394.4052	.0448	34	11.4		M+Na=418
6	383.8524	.1696	21	44.2		
7	553.506	.3162	13	57.1		M+H=517
8	564.0589	.1327	86	23.5		M+H=528
9	633.0311	.1667	-	13.2		M+H=535

Table 2 below sets forth the data for mass spectra and the inhibition of nitrendipine binding for selected compounds of Formula IIa.


Table 2



Compound Number	R ₂	R ₅	R ₈	Nitrendipine Binding IC ₅₀ (nM)	Mass Spectroscopy M±H/ M+Na
10	H	F		17	558
11	H	F		96	564
12	H	F	(CH ₂) ₂ OC(O)CH ₃	582	496
13	H	F		418	522
14	H	F	(CH ₂) ₂ OC(O)CH(CH ₃) ₂	60	524
15	H	H	(CH ₂) ₂ OH	20000	436
16	H	H		40	554
17	H	H	(CH ₂) ₂ OC(O)CH(CH ₃) ₂	36	506
18	Cl	H		21	600
19	Cl	H		18	538
20	H	F	(CH ₂) ₂ OH	4362	455
21	H	H	(CH ₂) ₃ OH	560	426

What is claimed is:

1. A compound of Formula I,



Formula I

or a pharmaceutically acceptable salt thereof, wherein

- (a) R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of H, OH, halogen, cyano, NO_2 , alkyl, C_{1-8} alkoxy, C_{1-8} alkylsulfonyl, C_{1-4} carboalkoxy, C_{1-8} alkylthio, difluoromethoxy, difluoromethylthio, trifluoromethyl and oxadiazole (formed by R_1 and R_2);

- (b) R_6 is selected from the group consisting of H, C_{1-5} straight or branched alkyl, aryl, 3-piperidyl, N-substituted 3-piperidyl, N-substituted 2-pyrrolidinyl methylene and substituted alkyl, wherein

said N-substituted 3-piperidyl and said N-substituted 2-pyrrolidinyl methylene may be substituted with C_{1-8} straight or branched chain alkyl or benzyl, and said substituted alkyl may be substituted with C_{1-8} alkoxy, C_{2-8} alkanoyloxy, phenylacetyloxy, benzoyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, carboalkoxy or $\text{NR}'\text{R}''$, wherein

(i) R' and R" are independently selected from the group consisting of H, C₁₋₈ straight or branched alkyl, C₃₋₇ cycloalkyl, phenyl, benzyl and phenethyl, or (ii) R' and R" together form a heterocyclic ring selected from the group consisting of piperidino, pyrrolidino, morpholino, thiomorpholino, piperazino, 2-thieno, 3-thieno and an N-substituted derivative of said heterocyclic rings, said N-substituted derivative being substituted with H, C₁₋₈ straight or branched alkyl, benzyl, benzhydryl, phenyl and/or substituted phenyl (substituted with NO₂, halogen, C₁₋₈ straight or branched chain alkyl, C₁₋₈ alkoxy and/or trifluoromethyl);

(c) R₇ is selected from the group consisting of H, amino, alkyl, aryl, trifluoromethyl, alkoxymethyl, 2-thieno and 3-thieno;

(d) R₉ is oxygen or sulfur; and

(e) n is an integer from 1 to 4.

2. The compound of claim 1, wherein R₉ is oxygen.

3. The compound of Claim 1, wherein R₆ is selected from the group consisting of methyl and -(CH₂)₂N(CH₃)CH₂PH.

4. The compound of Claim 1, wherein R₇ is methyl.


5. The compound of Claim 1, wherein R₁, R₂, R₃, R₄, and R₅ are independently selected from the group consisting of H, halogen and NO₂.

6. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(3-nitrophenyl), 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.
- 5 7. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, methyl ester, 1,1-dioxide.
- 10 8. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.
- 15 9. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(3-nitrophenyl), methyl ester, 1,1-dioxide.
- 20 10. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(2-nitrophenyl), methyl ester, 1,1-dioxide.
- 25 11. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(3-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, methyl ester, 1,1-dioxide.
- 30 12. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(3-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.
13. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 2,3,6,9-tetrahydro-7-methyl-9-(2-nitrophenyl), 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.

14. The compound of Claim 1 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl, 2-[methyl(phenylmethyl)amino]ethyl ester, 1,1-dioxide.

5

15. The compound of Formula (II), wherein



10

- (a) R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of hydrogen, OH, halogen, cyano, NO_2 , alkyl, C_{1-8} alkoxy, C_{1-8} alkylsulfonyl, C_{1-4} carboalkoxy, C_{1-8} alkylthio, difluoromethoxy, difluoromethylthio, trifluoromethyl and oxadiazole (formed by R_1 and R_2);

15

- (b) R_7 is selected from the group consisting of H, amino, alkyl, aryl, trifluoromethyl, alkoxymethyl, 2-thieno and 3-thieno;

20

- (c) R_8 is selected from the group consisting of -alkyl-OH, alkylamine, lactone, cyclic carbonate, alkyl-substituted cyclic carbonate, aryl-substituted cyclic carbonate, -aryl-C(O)OR', -alkyl-aryl-C(O)OR', -alkyl-OC(O)R', -alkyl-C(O)R', -alkyl-C(O)OR', -alkyl-N(R'')C(O)R', and -alkyl-N(R'')C(O)OR', wherein

R' and R'' are independently selected from the group consisting of hydrogen, amino, alkyl, aryl, aryl-fused cycloalkyl and heterocyclyl, the amino, alkyl, aryl, aryl-fused cycloalkyl and heterocyclyl being optionally substituted with halogen, cyano, NO₂, lactone, amino, alkylamino, aryl-substituted alkylamino, amide, carbamate, carbamoyl, cyclic carbonate, alkyl, halogen-substituted alkyl, arylalkyl, alkoxy, heterocyclyl and/or aryl (the aryl being optionally substituted with OH, halogen, cyano, NO₂, alkyl, amino, dimethylamino, alkoxy, alkylsulfonyl, C₁₋₄ carboalkoxy, alkylthio and/or trifluoromethyl); and

(d) R₉ is oxygen or sulfur.

16. The compound of Claim 15, wherein R₉ is oxygen.

17. The compound of Claim 15, wherein R₇ is methyl, and R₁, R₂, R₃, R₄, and R₅ are independently selected from hydrogen, halogen, trifluoromethyl and NO₂.

18. The compound of Claim 15, wherein R₈ is selected from -alkyl-OH, lactone, cyclic carbonate, alkyl-substituted cyclic carbonate, aryl-substituted cyclic carbonate and -alkyl-OC(O)R'.

19. The compound of Claim 15 which is 5H-[1,4]oxathiepine[6,5-b]pyridine-8-carboxylic acid, 9-(2,3-dichlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, 1,1-dioxide.


20. The compound of Claim 15 which is 5H-[1,4]oxathiepine[6,5-b]pyridine-8-carboxylic acid, 9-(2,3-dichlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, (2-oxo-5-phenyl-1,3-dioxol-4-yl)methyl ester, 1,1-dioxide.

21. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-hydroxyethyl ester, 1,1-dioxide.
- 5 22. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(2-methyl-1-oxopropoxy)ethyl ester, 1,1-dioxide.
- 10 23. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(2-methyl-1-oxopropoxy)ethyl ester, 1,1-dioxide.
- 15 24. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-[(cyclopropylcarbonyl)oxy]ethyl ester, 1,1-dioxide.
- 20 25. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(acetyloxy)ethyl ester, 1,1-dioxide.
- 25 26. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-[(cyclohexylcarbonyl)oxy]ethyl ester, 1,1-dioxide.
27. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chloro-6-fluorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 2-(benzoyloxy)ethyl ester, 1,1-dioxide.
- 30 28. The compound of Claim 15 which is 5*H*-[1,4]oxathiepine[6,5-*b*]pyridine-8-carboxylic acid, 9-(2-chlorophenyl)-2,3,6,9-tetrahydro-7-methyl-, 3-(benzoyloxy)propyl ester, 1,1-dioxide.


- 5 29. A pharmaceutical composition comprising the compound of Claim 1 or 15 and a pharmaceutically acceptable carrier.
- 10 30. A method of treating a subject suffering from a disorder whose alleviation is mediated by the reduction of calcium ion influx into cells whose actions contribute to the disorder, which method comprises administering to the subject a therapeutically effective dose of the pharmaceutical composition of Claim 29.
- 15 31. The method of Claim 30, wherein the disorder is selected from the group consisting of hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, a urinary tract disorder, a gastrointestinal motility disorder and a cardiovascular disorder.
- 20 32. The method of Claim 31, wherein the disorder is asthma.
33. The method of Claim 31, wherein the cardiovascular disorder is selected from the group consisting of hypertension, ischemia, angina, congestive heart failure, myocardial infarction and stroke.
- 25 34. A method of inhibiting in a subject the onset of a disorder whose alleviation is mediated by the reduction of calcium ion influx into cells whose actions contribute to the disorder, which method comprises administering to the subject a prophylactically effective dose of the pharmaceutical composition of Claim 29.

30


35. The method of Claim 34, wherein the disorder is selected from the group consisting of hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, a urinary tract disorder, a gastrointestinal motility disorder and a cardiovascular disorder.
36. The method of Claim 35, wherein the disorder is asthma.
37. The method of Claim 35, wherein the cardiovascular disorder is selected from the group consisting of hypertension, ischemia, angina, congestive heart failure, myocardial infarction and stroke.
38. The method of Claim 34, wherein the subject has normal or low blood pressure.
39. An apparatus for administering to a subject the pharmaceutical composition of Claim 29, comprising a container and the pharmaceutical composition therein, wherein the container has a means for delivering to the subject a therapeutic and/or prophylactic dose of the pharmaceutical composition.
40. A process for preparing the compound of Claim 1, comprising the steps of
- (a) reacting the compound of Formula 1a with the compound of Formula 1b to form the compound of Formula 1c;



1a





1b



1c




- (b) treating the compound of Formula 1c with NaOH to form the compound of Formula 1d;



- (c) treating the compound of Formula 1d with m-chloroperoxybenzoic acid and CHCl_3 to form the compound of Formula 1e;

5

- (d) treating the compound of Formula 1e with Jones Reagent and acetone to form the compound of Formula 1f; and



- (e) reacting the compound of Formula 1f with the compounds of Formulae 1g and 1h to form the compound of Claim 1.

10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/17310

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D497/04 C07D495/04 A61K31/4365 A61P9/00 A61P11/00
A61P27/06 A61P37/08 A61M11/00 //(C07D497/04, 327:00,
221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 462 696 A (ORTHO PHARMACEUTICAL CORP.) 27 December 1991 (1991-12-27) cited in the application the whole document	1-40
Y	EP 0 241 281 A (ORTHO PHARMACEUTICAL CORP.) 14 October 1987 (1987-10-14) cited in the application the whole document -/-	1-40

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 November 2000

Date of mailing of the international search report

08/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/17310

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DODD J.H. ET AL.: "Design and discovery of RWJ 22108- A novel bronchoselective calcium channel blocker" DRUG DESIGN AND DISCOVERY., vol. 15, no. 3, 1998, pages 135-148, XP000972157 HARWOOD ACADEMIC PUBLISHERS GMBH., XX ISSN: 1055-9612 cited in the application the whole document</p> <p>-----</p>	1-40

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/17310

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 462696 A	27-12-1991	US 5075440 A	24-12-1991
		AT 126231 T	15-08-1995
		AU 651580 B	28-07-1994
		AU 7635491 A	07-11-1991
		CA 2041594 A	04-11-1991
		CN 1056880 A,B	11-12-1991
		CN 1118783 A,B	20-03-1996
		DE 69111915 D	14-09-1995
		DE 69111915 T	04-01-1996
		DK 462696 T	18-09-1995
		ES 2079570 T	16-01-1996
		FI 912124 A,B,	04-11-1991
		GR 3017305 T	31-12-1995
		HK 51496 A	29-03-1996
		HU 60745 A	28-10-1992
		IE 68524 B	26-06-1996
		IL 97999 A	10-06-1997
		JP 4225986 A	14-08-1992
		KR 195345 B	15-06-1999
		NO 179411 B	24-06-1996
		NZ 237988 A	25-09-1992
		PT 97547 A,B	31-01-1992
		ZA 9103319 A	27-01-1993
		ZW 5291 A	06-01-1993
EP 241281 A	14-10-1987	US 4777167 A	11-10-1988
		US 4705785 A	10-11-1987
		AT 109151 T	15-08-1994
		AU 7114887 A	15-10-1987
		CA 1310967 A	01-12-1992
		CN 1028759 B	07-06-1995
		CN 1102185 A	03-05-1995
		DE 3750271 D	01-09-1994
		DE 3750271 T	24-11-1994
		DK 4494 A	11-01-1994
		DK 147392 A	08-12-1992
		DK 180487 A,C	10-10-1987
		ES 2060597 T	01-12-1994
		FI 871535 A	10-10-1987
		FI 93454 B	30-12-1994
		HK 32395 A	17-03-1995
		HU 47117 A,B	30-01-1989
		IE 63854 B	14-06-1995
		JP 2613757 B	28-05-1997
		JP 8208659 A	13-08-1996
		JP 2613758 B	28-05-1997
		JP 8208660 A	13-08-1996
		KR 9514868 B	16-12-1995
		NO 871481 A,B,	12-10-1987
		NZ 219761 A	24-02-1989
		PH 26673 A	13-09-1992
		PH 26186 A	18-03-1992
		PH 26187 A	18-03-1992
		PT 84648 B	29-12-1989
		SG 171294 G	28-04-1995
		AU 590067 B	26-10-1989
		HU 201942 B	28-01-1991
		JP 2561269 B	04-12-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/17310

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 241281	A	JP 62289582 A	16-12-1987
		US 4845225 A	04-07-1989
		ZA 8702535 A	30-11-1988
<hr/>			